Oseltamivir is Protective for In-Patient Mortality in PCR Confirmed Influenza B and Influenza A(H3N2) Infections in an Historic Cohort of 1,048 Patients Hospitalised During the 2016-17 and 2017-18 Influenza Seasons
Journal of Infection(2023)
摘要
Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.
更多查看译文
关键词
Historic Cohort study,Influenza B,Influenza A (H3N2) in-patient mortality,PCR,Multiplex PCR,Logistic regression,Multivariable logistic regression
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要